General company presentation
Evotec SE, Company presentation, May 2024
Disclaimer
This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.
Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward- looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward- looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.
PAGE 2
- Together for Medicines that Matter
- Shared R&D
- Just - Evotec Biologics
- Financials
PAGE 3
The core idea of Evotec - evolutionary technology
"The goal of Evolution is not
one single human, it is mankind."
Eigen's theories about self-organisation of complex molecules and his development of the evolution machine founded a new branch of science - evolutionary biotechnology.
Manfred Eigen (1927-2019)
Co-founder of Evotec, Nobel Prize 1967
PAGE 4 | Evotec was founded 1993 |
Accelerating medicines that matter
About us
4,000++ scientists empowering our partners
Across all disciplines and disease areas from target to commercial manufacturing
Co-creating pipelines
Leveraging our assets, targets or proprietary platforms for licensing, co-development or potential NewCo creation, frequently combining with Partners' programs, and ideas
R&D Biotech that offers accelerated, high-value pipeline co-creation, and R&D solutions
Performance - "Beyond FTEs"
Collaborating with "end in mind", result-driven partnership models
Track record - highest quality, most capital-efficient execution
State-of-the-art services as core offering for partners
PAGE 5
Scientific AND operational excellence are both essential for our success
Benefits of increased emphasis on Operational excellence
Shared R&D - From target to patient
Discovery of next generation drugs with higher efficacy and probability of success through industrialised PanOmics approach towards molecular disease understanding and E.iPSC disease modeling platform.
In-vitro & in-silico prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical.
Design and execution of best strategy for rapid entry into crucial first in human studies and further advancement into clinical supply.
Just - Evotec Biologics - Global access to biotherapeutics
Design and application of innovative technologies from discovery to commercial supply to dramatically expand global access to biotherapeutics.
Integrated continuous manufacturing platforms operating within cGMP facilities that employ autonomous clean room technology for the cost-efficient production of antibodies, next- generation biologics and biosimilar products.
PAGE 6
A shared economy model in R&D as basis for success
A stable foundation
>500 | ~47% | RoW |
Europe 28% byRevenueregion 60% USA | ||
12% | ||
Active partners | Revenue share with | |
TOP 10 partners |
NFP, Academic, | |||
Foundations | |||
>93% | 102 | Top 20 | 12% |
by partner 35% Biotech | |||
Pharma | |||
37% | Revenue | ||
Repeat | No. of partners with | ||
business | > € 1 m revenues | % | |
15 | |||
Large Biotech / | |||
Mid-sized Pharma |
PAGE 7
Sustainable growth enabled by commitment, culture, values & people
Selected ESG-KPIs
75% | 33% | 32% | ||||||
25% | ||||||||
Evotec SE | Share of PhDs | Women in Leadership | ||||||
Peers without ´ | Peers with | |||||||
SBTi targets | SBTi targets | |||||||
EcoVadis Score | 93 | 46% | ||||||
52% | Men | |||||||
39% | ||||||||
Evotec: 60 | ~5,000x | |||||||
talent | ||||||||
Nationalities | ||||||||
0% | 54% | |||||||
4% | 5% | |||||||
Women | ||||||||
0-2525-45 | 45-6565-8585-100 | |||||||
PAGE 8 | Derived from company information from: Charles River, Catalent, Wuxi Apptech, Wuxi Bio, Sartorius, Lonza, Qiagen, Eurofins, Danaher, Abcellera, Fate Therapeutics, Sana Biotechnology, Schrodinger, Recursion, Exscientia |
The growing "iceberg" of first & best-in-class treatment options
>140 co-owned projects
Inflammation & | ||||||||
Neuroscience & pain | Oncology | Metabolic diseases | Immunology1 | Virology, Anti-bacterial & Global health | ||||
Approved | Jingxin | SK Bio | ||||||||||||||||||
PhIII | ||||||||||||||||||||
PhII | Carrick | Carrick | Carrick | Carrick | Sernova | Topas | ||||||||||||||
Clinical | ||||||||||||||||||||
Centrexion | Bayer | Topas | ||||||||||||||||||
PhI | Exscientia | |||||||||||||||||||
BMS | Kazia | Immunitas | Conba | Exscientia | NIH | |||||||||||||||
ND | ND | ND | ND | EVT | EVT | ND | EVT | EVT | ||||||||||||
ND | ND | ND | ND | EVT | EVT | ND | EVT | EVT | ||||||||||||
ND | ND | ND | ND | EVT | EVT | ND | EVT | EVT | EVT | |||||||||||
ND | ND | ND | ND | ND | EVT | ND | EVT | EVT | EVT | EVT | EVT | |||||||||
ND | ND | ND | ND | ND | EVT | ND | EVT | EVT | EVT | EVT | EVT | |||||||||
Pre-clinical & | ND | ND | ND | ND | ND | EVT | EVT | ND | EVT | EVT | EVT | EVT | EVT | |||||||
Discovery | ND | ND | ND | ND | ND | EVT | EVT | ND | EVT | EVT | EVT | ND | EVT | EVT | ||||||
ND | ND | ND | EVT | ND | ND | ND | EVT | EVT | ND | ND | EVT | EVT | ND | ND | ND | EVT | EVT | |||
ND | ND | ND | EVT | ND | ND | ND | EVT | EVT | ND | ND | EVT | EVT | ND | EVT | ND | ND | ND | EVT | EVT | |
ND | ND | ND | EVT | ND | ND | ND | EVT | EVT | ND | ND | EVT | EVT | ND | EVT | ND | ND | ND | EVT | EVT |
>50
>120
Partnered Pipeline | Unpartnered Pipeline | Equity Pipeline | Bridges Pipeline | ||||
PAGE 9 | 1 Also includes Women's Health, Respiratory projects |
The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed | |
Status as of 31 December 2023 |
Shared R&D - Discovery of next generation drugs with higher efficacy and probability of success
PAGE 10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Evotec SE published this content on 21 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2024 13:18:08 UTC.